



**Indication:**

AMPYRA<sup>®</sup> (dalfampridine) is indicated to improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

**Important Safety Information:**

- AMPYRA is contraindicated in patients with history of seizure, moderate or severe renal impairment (CrCl  $\leq$  50 mL/min), or history of hypersensitivity to AMPYRA or 4-aminopyridine.
- AMPYRA can cause seizures. The risk of seizures increases with increasing doses. Permanently discontinue AMPYRA if seizure occurs. In the post-marketing period seizures have been reported. The majority of seizures occurred at the recommended dose, in patients without a history of seizures, and generally within days to weeks of starting therapy.
- AMPYRA has not been evaluated in patients with history of seizures or with epileptiform activity on an EEG, as these patients were excluded from clinical trials. The risk of seizures in patients with epileptiform activity on an EEG is unknown, and could be substantially higher than that observed in clinical studies.
- Avoid concomitant use of AMPYRA with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same. Instruct patients to discontinue use of any product containing 4-AP prior to initiating AMPYRA to reduce the potential for dose-related adverse reactions.
- AMPYRA can cause anaphylaxis and severe allergic reaction. Signs and symptoms included respiratory compromise, urticaria, and angioedema of the throat or tongue. If an anaphylactic or other serious allergic reaction occurs, permanently discontinue AMPYRA.
- AMPYRA is cleared predominantly by the kidneys. The risk of seizures in patients with mild renal impairment (CrCl 51–80 mL/min) is unknown, but AMPYRA plasma levels in these patients may approach those seen at a dose of 15 mg twice daily, a dose that may be associated with an increased risk of seizures. Estimated CrCl should be known before initiating AMPYRA and monitored at least annually during treatment.
- The most common adverse reactions (incidence  $\geq$  2% and at a rate greater than placebo) for AMPYRA in MS patients were urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, and pharyngolaryngeal pain.
- The risk of adverse reactions, including seizures, increases with increasing AMPYRA doses. There is no evidence of additional benefit at doses greater than 10 mg twice daily.
- Concomitant use with OCT2 inhibitors (e.g., cimetidine) may cause increased exposure to AMPYRA and potential risk of seizures.
- There are no adequate and well-controlled studies of AMPYRA in pregnant women. AMPYRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- It is not known if AMPYRA passes into breast milk. Discontinue AMPYRA or nursing, taking into consideration the importance of AMPYRA to the mother.
- Safety and effectiveness of AMPYRA in patients younger than 18 years have not been established.
- Clinical studies of AMPYRA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Because elderly patients are more likely to have decreased renal function, it is important to know the estimated CrCl before initiating AMPYRA.

Please see the Full Prescribing Information available at [www.ampyra.com/prescribing-information.pdf](http://www.ampyra.com/prescribing-information.pdf)

# AMPYRA® Patient Support Services Center

## Phone 888-881-1918

Please read the following statements carefully, then sign and date where indicated on the previous page.



### A. PATIENT AUTHORIZATION

By signing this authorization, I authorize my health plans, physicians, and pharmacies (collectively, my “Providers”) to disclose my personal health information relating to my medical condition, treatment, care management, and health insurance, as well as information provided on this form and any prescription (collectively, “Personal Health Information”), to Acorda Therapeutics, Inc. (“Acorda”) and its representatives, agents, and contractors, including but not limited to Acorda’s AMPYRA Patient Support Services Center operated by The Lash Group, Inc. on behalf of Acorda (collectively “the Entities”) for purposes of (1) providing services to me by the AMPYRA Patient Support Services Center; (2) facilitating the provision of products, supplies or services by Acorda; (3) registering me in any applicable Acorda product registration program; (4) evaluating the effectiveness of Acorda’s AMPYRA education programs and (5) enrolling me in Acorda’s Free 60 Day Trial, patient assistance program, and/or copay mitigation program (if one or more such programs apply to me). I understand that my pharmacies will disclose to the Entities certain personal health information regarding the dispensing of my Ampyra prescription and that such disclosure will result in remuneration to my pharmacies. I understand that once my Personal Health Information is disclosed to the Entities under this authorization, it is no longer protected by Federal privacy laws and may be further disclosed by the Entities; however, Acorda agrees to protect my information and only use and/or disclose it for the purposes described above, or as I may further authorize in writing, or as permitted or required by law. I understand that I may refuse to sign this authorization. I understand, however, that if I do not sign this authorization, I may not be able to receive assistance through the AMPYRA Patient Support Services Center. I understand that I am entitled to a copy of this authorization. I understand that I may cancel this authorization at any time by mailing a letter requesting such cancellation to Acorda Therapeutics, Inc., 9717 Key West Avenue, Rockville, MD 20850, but that this cancellation will not apply to any information already used or disclosed through this authorization before notice of the cancellation is received by each of the Entities. This authorization expires ten (10) years from the date signed on the previous page.

### B. PATIENT MARKETING CONSENT

I further authorize the release of information provided in this enrollment form to Acorda Therapeutics, Inc. (“Acorda”) for the provision of education, training, and ongoing support on the use of AMPYRA. Acorda may provide me with educational or product-related informational materials. The Lash Group, Inc., which operates the AMPYRA Patient Support Services Center for Acorda, may receive compensation from Acorda for providing such services. I authorize Acorda to contact me with promotional materials related to my treatment, to use and give out my information to send me information or materials related to AMPYRA or any other related products or services in which I might be interested, to contact me occasionally to obtain feedback (for market research purposes) about Acorda, AMPYRA, or the AMPYRA Patient Support Services Center, to operate (and improve the quality of) the AMPYRA program, or otherwise as required or permitted by law. If I do not wish to receive information related to AMPYRA or any related products or services or to be contacted occasionally for market research purposes, I understand that I may call the AMPYRA Patient Support Services Center’s toll-free number, 888-881-1918 at any time.


## What You Need to Do to Receive Your AMPYRA® Delivery

Ask your doctor to include specific language such as “Dispense As Written” (DAW) on every one of your Ampyra prescriptions including refills to ensure you receive your branded AMPYRA.



AMPYRA Patient Support Services Center will contact you to verify your insurance and co-pay amount. To verify your insurance and co-pay amount, **you must speak to the representative** who calls.

These calls may be from unrecognizable 800/888 phone numbers.



A Pharmacy will call to arrange your AMPYRA delivery. To receive your AMPYRA, **you must speak to the representative** who calls you to confirm your shipment.

These calls may be from unrecognizable 800/888 phone numbers.

**Have questions?** Call AMPYRA Patient Support Services toll-free 1-888-881-1918 Monday through Friday, from 8 AM to 8 PM ET.